Scrip’s Five Must-Know Things – 30 October 2023

Audio roundup of selected biopharma industry content from Scrip over the past business week. In this episode: did Pfizer miss out on Roivant/Roche deal?; Padcev/Keytruda combo impresses in bladder cancer at ESMO; biggest upfront ever in Daiichi/Merck deal; Rybrevant at ESMO; and subcutaneous Leqembi could open up access. https://scrip.citeline.com/SC149266/Quick-Listen-Scrips-Five-MustKnow-Things